IBRX

The Week

ImmunityBio (IBRX) closed the week up 0.37% at $8.08, outperforming the S&P 500 by roughly 0.28 percentage points. Trading was rangebound: the stock opened Monday at $7.88, hit a weekly low of $7.73 on Tuesday, then spiked to $8.28 on Wednesday on higher volume before easing back to $8.08 by Friday. There was no major company catalyst this week. The weekly amplitude was 6.98%, while average daily volume came in about a third below the 60-day median, suggesting thinner participation. The latest price sits at $8.08, with a negative price-to-book multiple of -8.18, reflecting its negative book value.

Analyst Ratings

Four brokers cover the name: three rate it buy and one rates it overweight, with no hold, underweight or sell ratings. The consensus is strong buy, with a consensus target of $12.75, about 57.8% above the latest price of $8.08. Targets range from $12 to $15, showing limited dispersion. ImmunityBio ranks 334 out of 507 within the biotechnology sector.

The Week Ahead

The US macro calendar is heavier next week. NFIB small business optimism lands on 8 September, with a prior reading of 99.8. On 10 September, final demand PPI, initial jobless claims, existing home sales and wholesale sales are all due, with PPI expected to accelerate. No company-specific earnings or events are scheduled within the week, but hotter inflation prints could shift risk appetite for biotech names and feed into volatility.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.